We recently demonstrated that treatment of diabetic nephropathy patients with the sodium-glucose cotransporter inhibitor (SGLT2i) dapaglifozin led to small but significant increases in serum phosphate, plasma PTH, and FGF23, independent of concomitant changes in eGFR or 24-h albumin excretion [83••]. Here, FGF23 is linked to diabetic kidney disease.